These results strongly suggest that positive transcriptional and epigenetic regulation of the MEOX2-GLI1 axis is involved in malignant lung tumor biology and cancer drug resistance versus responses, as previously suggested for MEOX2 in human lung cancer [21]; however, the mechanisms involved remain uncharacterized, and it is possible that a previously undescribed MEOX2 protein interaction on the GLI-1 gene promoter is responsible for lung cancer drug resistance and/or lung oncological therapy responses. The gene discussed is GLI1; the disease is lung carcinoma.